Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells

Delorme, Bruno; Basire, Agnès; Gentile, Carla; Sabatier, Florence; Monsonis, Frédéric; Desouches, C.; Blot‐Chabaud, Marcel; Uzan, Georges; Sampol, José; Dignat-George, Françoise

doi:10.1160/th05-07-0499

Cited by 115 publications

(99 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…39 Various further studies tried to dissect EPC phenotypes according to surface marker, for example, focusing on CD45 40 or endothelial markers, such as CD146. 41 Among CD34 ϩ cells, early EPCs appeared to be positive for CD45 and CD133 and negative for KDR; late EPCs, in contrast, were negative for CD45 and CD133 but positive for KDR. 40 On the other hand, CD34/CD146 ϩ mononuclear cells are able to form late EPCs with all of the known traits: cobblestonepattern, high proliferation, and expression of endothelial markers.…”

Section: Separated Cd14mentioning

confidence: 91%

Endothelial-Regenerating Cells

2010

View full text Add to dashboard Cite

Abstract-Atherosclerosis is the most common cause for cardiovascular diseases and is based on endothelial dysfunction.A growing body of evidence suggests the contribution of bone marrow-derived endothelial progenitor cells, monocytic cells, and mature endothelial cells to vessel formation and endothelial rejuvenation. To this day, various subsets of these endothelial-regenerating cells have been identified according to cellular origin, phenotype, and properties in vivo and in vitro. However, the definition and biology, especially of endothelial progenitor cells, is complex and under heavy debate. In this review, we focus on current definitions of endothelial progenitor cells, highlight the clinical relevance of endothelial-regenerating cells, and provide new insights into cell-cell interactions involved in endothelial cell rejuvenation. (Hypertension. 2010;55:593-599.)

show abstract

Section: Separated Cd14mentioning

confidence: 91%

Endothelial-Regenerating Cells

2010

View full text Add to dashboard Cite

show abstract

“…Human umbilical cord blood samples from healthy donors were collected in compliance with French legislation, and ECFCs were isolated as previously reported (8).…”

Section: Cell Preparation and Primingmentioning

confidence: 99%

Erythropoietin Pretreatment of Transplanted Endothelial Colony-Forming Cells Enhances Recovery in a Cerebral Ischemia Model by Increasing Their Homing Ability: A SPECT/CT Study

et al. 2016

Self Cite

View full text Add to dashboard Cite

Endothelial colony-forming cells (ECFCs) are promising candidates for cell therapy of ischemic diseases, as less than 10% of patients with an ischemic stroke are eligible for thrombolysis. We previously reported that erythropoietin priming of ECFCs increased their in vitro and in vivo angiogenic properties in mice with hindlimb ischemia. The present study used SPECT/CT to evaluate whether priming of ECFCs with erythropoietin could enhance their homing to the ischemic site after transient middle cerebral artery occlusion (MCAO) followed by reperfusion in rats and potentiate their protective or regenerative effect on blood-brain barrier (BBB) disruption, cerebral apoptosis, and cerebral blood flow (CBF). Methods: Rats underwent a 1-h MCAO followed by reperfusion and then 1 d after MCAO received an intravenous injection of either PBS (control, n 5 10), PBS-primed ECFCs (ECFC PBS , n 5 13), or erythropoietinprimed ECFCs (ECFC EPO , n 5 10). ECFC homing and the effect on BBB disruption, cerebral apoptosis, and CBF were evaluated by SPECT/CT up to 14 d after MCAO. The results were expressed as median 6 interquartile range for ipsilateral-to-contralateral ratio of the activity in middle cerebral artery-vascularized territories in each hemisphere. Histologic evaluation of neuronal survival and astrocytic proliferation was performed on day 14. Results: Erythropoietin priming increased homing of ECFCs to the ischemic hemisphere (ECFC PBS , 111.0% 6 16.0%; ECFC EPO , 146.5% 6 13.3%). BBB disruption was significantly reduced (control, 387% 6 153%; ECFC PBS , 151% 6 46% [P , 0.05]; ECFC EPO , 112% 6 9% [P , 0.001]) and correlated negatively with ECFC homing (Pearson r 5 20.6930, P 5 0.0002). Cerebral apoptosis was significantly reduced (control, 161% 6 10%; ECFC PBS , 141% 6 9% [P , 0.05]; ECFC EPO ,118% 6 5% [P , 0.001]) and correlated negatively with ECFC homing (r 5 20.7251, P , 0.0001). CBF was significantly restored with ECFCs and almost totally so with erythropoietin priming (control, 72% 6 2%; ECFC PBS , 90% 6 4% [P , 0.01]; ECFC EPO , 99% 6 4% [P , 0.001]) and correlated positively with ECFC homing (r 5 0.7348, P , 0.0001). Immunoblocking against the CD146 receptor on ECFCs highlighted its notable role in ECFC homing with erythropoietin priming (ECFC EPO , 147% 6 14%, n 5 4; ECFC EPO with antibody against CD146, 101% 6 12%, n 5 4 [P , 0.05]). Conclusion: Priming with erythropoietin before cell transplantation is an efficient strategy to amplify the migratory and engraftment capacities of ECFCs and their beneficial impact on BBB disruption, apoptosis, and CBF.

show abstract

“…Our own experience shows that CD 146 positive cells were CD 133 negative 91 . Very recently, however, Delorme and coworkers clearly demonstrated EPC among a population of cells isolated by CD-146-driven immunomagnetic isolation 92 . Although their findings need corroboration, new protocols of immunomagnetic isolation may be needed to exclude EPC.…”

Section: Cec and Epc -An Ongoing Controversymentioning

confidence: 99%